OPKO Health (NASDAQ:OPK) – Barrington Research boosted their Q2 2018 EPS estimates for OPKO Health in a report released on Wednesday, May 9th, Zacks Investment Research reports. Barrington Research analyst M. Petusky now anticipates that the biotechnology company will post earnings per share of ($0.08) for the quarter, up from their prior forecast of ($0.16). Barrington Research currently has a “Buy” rating and a $7.00 price target on the stock. Barrington Research also issued estimates for OPKO Health’s Q3 2018 earnings at ($0.08) EPS, Q4 2018 earnings at ($0.07) EPS, FY2018 earnings at ($0.31) EPS, FY2019 earnings at ($0.20) EPS, FY2020 earnings at ($0.04) EPS and FY2021 earnings at $0.11 EPS.
Several other research firms have also recently issued reports on OPK. Zacks Investment Research cut shares of OPKO Health from a “hold” rating to a “sell” rating in a research note on Wednesday, January 24th. JPMorgan Chase cut shares of OPKO Health from a “neutral” rating to an “underweight” rating and set a $7.00 target price on the stock. in a research note on Friday, March 2nd. BidaskClub upgraded shares of OPKO Health from a “strong sell” rating to a “sell” rating in a research note on Thursday, April 19th. Cantor Fitzgerald restated a “buy” rating and set a $20.00 target price on shares of OPKO Health in a research note on Tuesday, May 8th. Finally, ValuEngine cut shares of OPKO Health from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $10.21.
Shares of OPK stock opened at $3.75 on Monday. OPKO Health has a one year low of $2.66 and a one year high of $7.25. The stock has a market cap of $2.08 billion, a P/E ratio of -12.93 and a beta of 1.59. The company has a current ratio of 1.10, a quick ratio of 0.94 and a debt-to-equity ratio of 0.03.
OPKO Health (NASDAQ:OPK) last announced its quarterly earnings data on Thursday, March 1st. The biotechnology company reported ($0.12) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.04). OPKO Health had a negative net margin of 31.27% and a negative return on equity of 8.76%. The firm had revenue of $193.70 million for the quarter, compared to analysts’ expectations of $307.44 million.
In other OPKO Health news, CEO Phillip Md Et Al Frost acquired 75,000 shares of the stock in a transaction dated Wednesday, March 7th. The shares were purchased at an average price of $3.29 per share, for a total transaction of $246,750.00. Following the purchase, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at $10,096,848.79. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, Director Robert Scott Fishel acquired 10,000 shares of the stock in a transaction dated Friday, April 13th. The stock was acquired at an average price of $3.02 per share, for a total transaction of $30,200.00. The disclosure for this purchase can be found here. Insiders bought a total of 1,626,867 shares of company stock worth $5,175,412 in the last quarter. Company insiders own 40.19% of the company’s stock.
Several large investors have recently modified their holdings of OPK. Ellington Management Group LLC purchased a new stake in OPKO Health in the 4th quarter worth approximately $112,000. State of Alaska Department of Revenue purchased a new stake in OPKO Health in the 4th quarter worth approximately $144,000. First Trust Advisors LP purchased a new stake in OPKO Health in the 4th quarter worth approximately $154,000. Castleview Partners LLC purchased a new stake in OPKO Health in the 1st quarter worth approximately $103,000. Finally, Xact Kapitalforvaltning AB purchased a new stake in OPKO Health in the 4th quarter worth approximately $179,000. Hedge funds and other institutional investors own 24.21% of the company’s stock.
OPKO Health Company Profile
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.